Welcome to our dedicated page for Scopus Biopharma news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on Scopus Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scopus Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scopus Biopharma's position in the market.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced plans for an exchange offer allowing shareholders to exchange common stock for X Units. Each X Unit consists of one share of common stock and one new warrant, with no cash consideration required. Holders can tender all, some, or none of their stock, maintaining unmodified shares. The X Warrants will be exercisable at $9.00 per share starting January 2, 2023. Additionally, the company will seek Nasdaq listing for the X Units and Warrants, enhancing shareholder value and long-term investment incentives.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced a $9 million follow-on public offering of 1,000,000 shares at $9.00 per share. The underwriters have a 45-day option to purchase an additional 150,000 shares. This offering is expected to close on January 29, 2021, subject to customary conditions. Proceeds will primarily fund the development of Scopus's lead drug candidate, a targeted immuno-oncology gene therapy. The Benchmark Company, LLC is the Sole Bookrunning Manager for this offering.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the successful completion of clinical lot manufacturing, a crucial step towards its Phase 1 clinical trial for non-Hodgkin's lymphoma. This milestone will enable the finalization of the investigational new drug (IND) application to the FDA. The company is developing a unique immuno-oncology gene therapy to treat multiple cancers, aiming to combine its lead drug candidate with checkpoint inhibitors like Keytruda. The management expressed confidence in the potential of upcoming clinical updates to enhance shareholder value.
Scopus BioPharma (Nasdaq: SCPS) has announced the appointment of several new members to its Board of Directors as part of its recent IPO and listing on the Nasdaq Global Market. The newly appointed directors are Raphael Hofstein, Lesley Russell, David Battleman, David Buckel, and David Weild IV, all recognized leaders in biopharmaceutical and capital markets. Chairman Joshua R. Lamstein emphasized the significant industry experience these new directors bring, aiming to enhance the company's mission of advancing therapeutics for cancer treatment.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the closing of its initial public offering, successfully selling 575,000 shares at $5.50 each. The offering included shares from the exercised over-allotment option. Proceeds will primarily fund the development of a novel immuno-oncology gene therapy targeting various cancers. The offering statement was filed with the SEC on December 14, 2020. The transaction was managed by The Benchmark Company, LLC, with Joseph Gunnar & Co., LLC as co-manager.